Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKY-0515 in Huntington's Disease
NCT06873334Phase 3Active, not recruiting
- Sponsor
- Skyhawk Therapeutics
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of SKY-0515 in Huntington's disease (HD) (4 arms), sponsored by Skyhawk Therapeutics. Primary endpoints: Mutant Huntingtin Protein Levels at 12 months, Brain Volume at 12 months and 1 more. Started May 2025; status: active, not recruiting.
02
Drugs
SKY-0515
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT06873334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06873334.